In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Role of myocardial perfusion scintigraphy in decision-making process leading to coronary angiography in hospitalized elderly patients with suspected coronary artery disease

Session Poster Session 3

Speaker Assistant Professor Monika Stalc

Event : ESC Congress 2018

  • Topic : imaging
  • Sub-topic : Single Photon Emission Computed Tomography (SPECT)
  • Session type : Poster Session

Authors : M Stalc (Ljubljana,SI), M Dolenc Novak (Ljubljana,SI), N Jerman (Ljubljana,SI), M Trampus (Ljubljana,SI), B Guzic Salobir (Ljubljana,SI)

M. Stalc1 , M. Dolenc Novak1 , N. Jerman2 , M. Trampus2 , B. Guzic Salobir1 , 1University Medical Centre of Ljubljana, Department for nuclear medicine - Ljubljana - Slovenia , 2University of Ljubljana, Faculty of Medicine - Ljubljana - Slovenia ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 568

Introduction: Atypical ischaemic symptoms and comorbidities in the elderly population make the diagnosis of coronary artery disease (CAD) challenging. Since the role of myocardial perfusion imaging (MPI) in the diagnostic assessment of CAD has been extensively evaluated in middle-aged ambulatory patients, there is limited data for its application in elderly hospitalized patients, particularly those ≥75 years of age.

Purpose: To assess the impact of MPI on decision for coronary angiography in hospitalized elderly patients (≥75 years) with suspected CAD in comparison to younger patients.

Methods: In the retrospective study, data of consecutive hospitalized patients with suspected CAD admitted to MPI from June 2014 to June 2017 were analysed. Patients were categorized into “elderly” (≥75 years) and “younger” (<75 years) groups. The clinical characteristics and coronary angiography rates were identified by manually reviewing the patients' records.

Results: 362 patients with mean age 71±3 years (range 30–92 years) (43.4%women, 84% arterial hypertension, 34% diabetes mellitus, 41.7% previous myocardial infarction or revascularization, 88.9% chest pain) were studied. 155 patients were ≥75 years old (mean age 81.4±4.4). Elderly patients had a higher prevalence of women (55.5% vs. 34.3%, p<0.01) and arterial hypertension (89% vs. 79%, p<0.01) and were less likely to have hyperlipidemia (70.1% vs. 81.0%, p<0.05) and history of smoking (4.5% vs. 23.0%, p<0.01) than younger patients. Elderly had more concomitant diseases than younger patients (2±1.5 vs. 1.5±1.5, p<0.01). All patients underwent a 2-day stress/rest 99mTc tetrofosmin (Myoview, GE Healthcare) myocardial perfusion single photon emission computed tomography. Elderly patients underwent significantly more pharmacological stress testing than younger (94.2% vs. 75%, p<0.01). MPI confirmed ischaemia in 168 (46.4%) patients. Ischaemia was more prevalent in younger than in elderly patients (51.7% vs. 39.3%, p<0.05). Result of MPI had a significant influence on the decision for coronary angiography in both groups (performed in 75.6% of patients with ischaemia vs. 7% patients without ischaemia, p<0.001). The referral rate for cardiac catheterization was not significantly different between elderly and younger patients with ischaemia (68.9% vs 79.4%, NS). Ischaemia on MPI was the most predictive variable for referral to coronary angiography in elderly (odds ratio 23.0, p<0.001).

Conclusions: MPI is a safe non-invasive diagnostic method in elderly hospitalized patients. Abnormal MPI is a powerful predictor for in-hospital coronary angiography independent of the patient's age. Thus, MPI is an effective gatekeeper for coronary angiography in both, elderly and younger hospitalized patients with suspected CAD.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are